For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
5-Amino-1MQ (5-Amino-1-Methylquinolinium) is a synthetic small molecule NNMT inhibitor, not a peptide, included in this series because it circulates widely in peptide research contexts. NNMT (nicotinamide N-methyltransferase) methylates nicotinamide, depleting NAD+ precursors and consuming SAM. Inhibiting NNMT raises intracellular NAD+, elevates SAM, and suppresses lipogenesis in adipocytes. The Neelakantan 2018 mouse study (11 days, diet-induced obese) showed significant fat mass and body weight reduction without food intake changes. Babula 2024 (28 days, diet-induced obese mice) confirmed dose-dependent fat mass limitation, improved insulin sensitivity, and attenuated hepatic steatosis, while also identifying MAO-A inhibition as an off-target activity. Dimet-Wiley 2024 (aged mice, 8 weeks) showed approximately 40% greater grip strength in NNMT-inhibitor-treated sedentary mice versus controls. No human clinical trial has been published.
5-Amino-1MQ is not a peptide. It is a small molecule quinolinium compound with a molecular weight of approximately 159 Da, far below the minimum size of even the simplest peptides. It is included in this series because it circulates widely in peptide research communities and peptide vendor catalogues, and because readers searching for evidence on it deserve signal-quality analysis.
No human clinical trial of 5-Amino-1MQ or any NNMT inhibitor has been published as of March 2026. Multiple peer-reviewed reviews state this explicitly. The compound is currently administered to human patients by some longevity clinics in the USA despite the absence of any human safety data, Phase 1 dosing characterization, or regulatory authorization. 'No known side effects' in vendor marketing means 'no systematic adverse event data has been collected in humans,' not that side effects have been ruled out by trial.
The MAO-A off-target activity identified in Babula 2024 is a material safety concern that receives minimal coverage in vendor content. Monoamine oxidase A (MAO-A) inhibition affects the metabolism of serotonin, norepinephrine, and dopamine. Dietary tyramine interactions with MAO-A inhibitors can cause hypertensive crisis. This is a drug interaction profile familiar from classic antidepressants (phenelzine, tranylcypromine). Whether 5-Amino-1MQ produces clinically relevant MAO-A inhibition at physiological doses in humans is unknown but requires acknowledgment.
Nicotinamide N-methyltransferase (NNMT) is an enzyme expressed primarily in the liver and white adipose tissue that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (NAM), producing methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). Overactive NNMT depletes nicotinamide (reducing NAD+ precursor availability), consumes SAM (reducing the methyl donor pool needed for epigenetic regulation), and elevates homocysteine. Elevated NNMT expression is observed in white adipose tissue and liver of obese humans and animal models of metabolic syndrome, and NNMT overactivity correlates with insulin resistance and fat accumulation.
Landmark work from Kraus et al. (2014, Nature) demonstrated that NNMT knockdown in adipose and liver tissue of mice protected against diet-induced obesity by raising energy expenditure via NAD+-dependent signaling. This validated NNMT as a therapeutic target but required a pharmacological tool.
Professor Stanley Watowich's group at the University of Texas Medical Branch identified 5-amino-1-methylquinolinium (5-Amino-1MQ) as a selective, membrane-permeable NNMT inhibitor in 2017 through a medicinal chemistry program targeting the NNMT nicotinamide binding site. 5-Amino-1MQ is taken orally, crosses cell membranes efficiently (confirmed in Caco-2 bidirectional permeability assays), and inhibits NNMT without inhibiting related SAM-dependent methyltransferases (DNMT1, PRMT3, COMT) or NAD+ salvage pathway enzymes (NAMPT, SIRT1) at relevant concentrations.
5-Amino-1MQ inhibits NNMT, an enzyme that in normal function catalyzes the transfer of a methyl group from SAM to nicotinamide, generating methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). When NNMT is overactive (as in obese adipose tissue), this reaction continuously depletes nicotinamide, which is the precursor to NMN and ultimately NAD+. Simultaneously, it depletes SAM, the universal methyl donor needed for DNA methylation and histone modification. Downstream consequences of NNMT overactivity include reduced NAD+ biosynthesis, impaired sirtuin activation, elevated homocysteine (a cardiovascular risk factor), and a permissive epigenetic environment for lipogenic gene expression.
By competitively inhibiting NNMT at the nicotinamide binding site, 5-Amino-1MQ redirects the metabolic flux. Nicotinamide accumulates rather than being methylated and wasted, making more substrate available for NAD+ biosynthesis via the salvage pathway (nicotinamide to NMN via NAMPT, then to NAD+). SAM levels rise as less is consumed by NNMT. The net effects observed in cell and animal studies include: elevated intracellular NAD+, elevated SAM, suppressed lipogenesis, increased mitochondrial activity, improved insulin sensitivity, and reduced adipocyte size.
In the Neelakantan 2018 study, 30 micromolar 5-Amino-1MQ in differentiated 3T3-L1 adipocytes produced statistically significant reduction in 1-MNA (p less than 0.05), elevated NAD+ and SAM confirmed by LC-MS/MS, and reduced lipid accumulation in treated adipocytes. In vivo in diet-induced obese mice (20 mg/kg three times daily subcutaneous, 11 days), treated animals showed significantly reduced body weight, white adipose mass, and adipocyte size versus controls with no change in food intake.
Babula 2024 confirmed the PK profile in DIO mice (oral, subcutaneous, and intravenous dosing) showing distribution to liver, adipose, and muscle, all metabolically relevant tissues. Importantly, Babula 2024 also identified MAO-A inhibition in a broad target panel screen. MAO-A catabolizes serotonin, norepinephrine, and dopamine; its inhibition is a clinically established effect with drug interaction consequences. Whether 5-Amino-1MQ reaches concentrations sufficient for clinically meaningful MAO-A inhibition in humans is unknown.
Neelakantan 2018 (diet-induced obese mice, 11 days): Treatment with 5-Amino-1MQ at approximately 34 mg/kg/day (subcutaneous) significantly reduced body weight, white adipose mass, and adipocyte size versus vehicle controls. Total plasma cholesterol was reduced. No change in food intake was observed, suggesting the mechanism is metabolic rather than anorexigenic. In vitro at 30 micromolar, 5-Amino-1MQ significantly reduced 1-MNA production in 3T3-L1 adipocytes (p less than 0.05 in pre-adipocytes; p less than 0.05 in mature adipocytes), elevated NAD+ and SAM by LC-MS/MS, and inhibited lipid accumulation. Selectivity against DNMT1, PRMT3, COMT, NAMPT, and SIRT1 was confirmed at relevant concentrations.
Babula 2024 (DIO mice, 28 days): 5A1MQ treatment dose-dependently limited body weight and fat mass gains, improved oral glucose tolerance (OGTT), suppressed hyperinsulinemia, attenuated hepatic steatosis on histology, and reduced liver weight and liver lipid markers. Mouse plasma PK confirmed tissue distribution to liver, adipose, and skeletal muscle. Oral, subcutaneous, and intravenous PK parameters were characterized. MAO-A inhibition was identified in a broad panel screen; clinical implications in humans unknown.
The preclinical evidence from the two published mouse studies is mechanistically coherent and effect sizes are meaningful. Weight and fat mass reduction without food intake change is a genuinely interesting metabolic phenotype. The 28-day Babula study adds oral PK characterization and confirms metabolic improvements. No human data exists. The MAO-A off-target finding in Babula 2024 is a material safety signal that requires human PK/PD characterization before the compound can be considered for human use.
Dimet-Wiley 2024 (aged female mice, 8 weeks): NNMTi-treated sedentary aged mice showed approximately 40% greater grip strength than sedentary controls. Exercised mice without NNMTi showed approximately 20% improvement. Exercise plus NNMTi combined showed approximately 60% improvement in grip strength versus sedentary controls, suggesting the mechanisms are additive rather than overlapping.
NNMTi treatment promoted improvements in intramyocellular lipid (IMCL) content and, combined with exercise, significantly increased gastrocnemius muscle fiber cross-sectional area. The proteome and metabolome analyses revealed distinct molecular signatures for NNMTi treatment versus exercise, supporting the additive effect interpretation.
The study used only aged female mice. Results in male mice, younger animals, or other species are unknown. Study duration was 8 weeks; long-term effects were not assessed.
The Dimet-Wiley 2024 result is one of the most striking preclinical findings for this compound: 40% grip strength improvement in sedentary aged mice from NNMTi treatment alone, with additive effects when combined with exercise. If this translates to humans, it would be highly relevant to sarcopenia. The critical limitation is that this is aged female mice only, and age-related sarcopenia research has a long history of impressive preclinical results that have not translated to human benefit. No human muscle function data for 5-Amino-1MQ exists.
Babula 2024: When 5A1MQ was screened against a broad panel of target proteins to characterize its pharmacological specificity, it demonstrated inhibitory activity against human MAO-A (monoamine oxidase A). The paper explicitly notes this as a possible contributor to improvements in oral glucose tolerance observed in the study, citing literature linking MAO-A inhibitors to improved glucose handling.
MAO-A context: MAO-A is an enzyme that metabolizes monoamine neurotransmitters including serotonin, norepinephrine, and dopamine. Classic irreversible MAO-A inhibitors (phenelzine, tranylcypromine) require strict dietary restrictions: tyramine, found in aged cheese, cured meats, fermented soy products, and red wine, is normally metabolized by intestinal MAO-A. When MAO-A is inhibited, tyramine accumulates and can trigger sympathomimetic reactions including severe hypertensive crisis. Even reversible MAO-A inhibitors (moclobemide) require dietary caution. MAO-A inhibitors also interact with multiple medications including SSRIs, serotonin syndrome risk.
Whether 5-Amino-1MQ achieves clinically meaningful MAO-A inhibition at human doses is unknown. The potency of 5-Amino-1MQ at MAO-A versus NNMT, the human pharmacokinetic behavior, and the tissue-specific concentrations in the gastrointestinal tract (where dietary tyramine interactions would occur) have not been characterized.
This is a material unresolved safety concern that is rarely discussed in vendor or community content about 5-Amino-1MQ. MAO-A inhibition is not a benign off-target effect: it has well-documented, potentially life-threatening dietary and drug interactions. Until human PK studies have characterized the MAO-A inhibition profile at physiological doses, and until dietary interaction studies have been completed, the MAO-A signal from Babula 2024 requires acknowledgment by anyone administering this compound to humans.
NNMT inhibition and direct NAD+ precursor supplementation (NMN, NR) both elevate intracellular NAD+ but through different mechanisms. NMN and NR directly provide substrates for NAD+ biosynthesis. 5-Amino-1MQ prevents the methylation of nicotinamide (NAM), leaving more NAM available to enter the salvage pathway and be converted to NMN by NAMPT, and then to NAD+.
The NNMT inhibition approach also elevates SAM (by reducing SAM consumption), which NMN and NR do not. The elevation of SAM may contribute independently to beneficial epigenetic modifications. Kraus et al. (2014) showed that NNMT knockout raised energy expenditure beyond what was explained by NAD+ alone, suggesting SAM-dependent epigenetic effects on metabolic gene expression contribute to the phenotype.
In vivo in mice, 5-Amino-1MQ elevated NAD+ in adipose tissue with confirmed on-target NNMT engagement (reduced 1-MNA). This confirmed pharmacological proof of concept for the mechanism.
The mechanistic distinction from NMN/NR is real: NNMT inhibition both prevents NAM waste and preserves SAM, while direct NAD+ precursors only address the substrate supply. Whether this dual effect confers superior metabolic benefit in humans versus NMN supplementation is unknown. Both approaches lack large-scale human RCT evidence. 5-Amino-1MQ's advantage in this comparison is theoretical; it has the additional disadvantage of the MAO-A safety signal that NMN/NR do not carry.
Injectable SC doses much lower than oral capsule doses of 50-150mg.
5-Amino-1MQ has no validated human pharmacokinetic or dosing data. The numeric dose values above (50 to 100 mg) are from longevity clinic and community consensus, not from any published human trial. Mouse effective doses ranged from approximately 20 mg/kg subcutaneous to 50 mg/kg oral. Direct conversion to human equivalent doses is not straightforward. MAO-A inhibition status at human doses is unknown. Until Phase 1 human PK and safety data are published, all human dosing is empirical and unvalidated.
Within this series, 5-Amino-1MQ is the only small molecule NNMT inhibitor and one of only three non-peptide compounds included (alongside NAD+ at order 30 and MK-677 at order 27). Its mechanism overlaps with NAD+ supplementation (both raise intracellular NAD+) but via a different upstream pathway; NNMT inhibition additionally raises SAM and reduces 1-MNA in a way direct NAD+ precursors do not. For fat loss, 5-Amino-1MQ's preclinical mechanism is completely orthogonal to GLP-1 agonists (appetite vs. intracellular metabolism), tirzepatide (dual incretin), and AOD-9604 (lipolysis), making it potentially complementary to any of these. The muscle preservation data from Dimet-Wiley 2024 has no close parallel in any other compound profiled in this series; if replicated in humans it would be uniquely valuable as a muscle-sparing adjunct to GLP-1-based weight loss. All of these comparisons remain hypothetical until human data exists.
5-Amino-1MQ has no published human clinical safety data. All safety information derives from preclinical studies.
In animal studies, 5-Amino-1MQ produced no observable adverse effects at the doses studied (up to approximately 34 mg/kg/day subcutaneous in mice, 11 days; up to 50 mg/kg/day oral in DIO mice over 28 days in Babula 2024). No organ toxicity, hematological abnormalities, or behavioral changes were documented. The compound did not inhibit related methyltransferases (DNMT1, PRMT3, COMT) or NAD+ salvage pathway enzymes (NAMPT, SIRT1) at relevant concentrations, indicating selectivity for NNMT.
The MAO-A off-target finding (Babula 2024) is the primary unresolved safety concern. MAO-A inhibitors are a well-established drug class (classic irreversible MAOIs including phenelzine and tranylcypromine; reversible MAOIs including moclobemide). At therapeutic doses, MAOIs produce a well-known drug interaction with tyramine-rich foods (aged cheeses, cured meats, fermented products): tyramine that is normally metabolized by intestinal and hepatic MAO-A accumulates and can trigger hypertensive crisis. Whether 5-Amino-1MQ achieves MAO-A inhibition at pharmacologically relevant concentrations in humans is currently unknown because no human PK study has been published.
The absence of food intake changes in mouse studies means the compound is not acting through anorexigenic pathways. Long-term effects on epigenetic methylation (via SAM accumulation and redirection of methyl group metabolism) have not been studied.
Some longevity clinics are administering 5-Amino-1MQ to human patients at doses of 50 to 100 mg daily without having completed Phase 1 safety studies. This is an off-label use of an unapproved research chemical, not a supervised investigational drug protocol.
5-Amino-1MQ represents genuinely interesting preclinical biology at an early but coherent stage. The target (NNMT) is validated by genetic knockdown experiments in mice. The mechanism (NAD+ restoration plus SAM preservation) is distinct from existing NAD+ supplementation approaches. The animal data shows real effects: meaningful fat mass reduction, improved insulin sensitivity, attenuated fatty liver, and (most strikingly) approximately 40% grip strength improvement in aged sedentary mice. These are not trivial preclinical signals.
The evidence base is entirely animal and in vitro. No human interventional trial has been published. No Phase 1 safety study has characterized pharmacokinetics, maximum tolerated dose, or adverse event profile in humans. The MAO-A off-target finding from Babula 2024 is a real concern that has not been resolved: MAO-A inhibition is associated with well-characterized dietary and drug interactions that could be serious. Some clinics are currently administering this compound to humans without this data.
Compared to GLP-1 agonists with multiple Phase 3 trials and regulatory approval for obesity, 5-Amino-1MQ is at the earliest possible stage of translational development. It has not been proven safe or effective in humans. It may well be both — the preclinical signal is strong enough to justify clinical investigation. But that investigation has not happened yet.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use